19th Annual EUR Bioassay Conference

23-25 September 2026

Seville, Spain

Welcome Back & Introduction

Laureen Little
Principal Consultant
Quality Services
BEBPA President

Day 1 - Intro Audience Surveys

i.1 How many BEBPA Conferences have you attended?



i.2 What type of organization do you work for?



i.3 What part of the organization do your work for?



i.4 What type of products do you work with? (Check all that apply)



i.5 What type of assays do you develop? (Check all that apply)



Day 1 Audience Surveys

Session 1: From Infancy to Pre-Puberty in a Bioassay (Early Development)

Session 2: The Bioassay as a Teenager: Fitting In With The Crowd (Automation & AI)

1.1 What do you think is the key scientific consideration when developing bioassays for multi-target analogues?



1.2 Would you apply the same acceptance criteria for the optimized-multitarget n-in-1 assay as for each single assay run independently?



1.3 As multiple target assays are integrated into one workflow, which risk becomes particularly important to control in your opinion?



Check back here in a few days for detailed results!

1.4 Do you use DoE for assay development? (Not including validation or robustness testing)



1.5 Do you do early development knowing that they will need to be automated?



Day 2 Audience Surveys

Session 3A: All Our Children Are Different (Product Specific Bioassays)

2.1 How would you rate your experience with ADCs (antibody drug conjugates)?



2.2 Does your organization currently develop, manufacture, or test ADCs?



2.3 Which area of ADC bioassays is most relevant to your work?



2.4 How confident are you in your understanding of global regulatory expectations for ADC bioassays?



2.5 In your experience, are global regulatory expectations for ADC bioassays sufficiently harmonized?



2.6 What do you consider the biggest challenge in ADC bioassay development?



2.7 When you think about ADC bioassays, what is the first challenge that comes to mind?

Check back here in a few days for detailed results!

2.8 Which statement best reflects your current view?



Day 3 Audience Surveys

Session 3B: All Our Children Are Different (Product Specific Bioassays)

3.1 Which regulatory region most influences your assay strategy?



3.2 Have you ever completely changed potency assays in late phase !!!?



3.3 Have you ever completely changed potency assays post commercialization?



3.4 For Novel ATMP such as siRNA, at what stage do you first include a MoA potency assay for release?



3.5 If you implement potency later than P1 or P2, how do you ensure product potency for release in these early phases?



3.6 Which Ligand format you have used to develop Ligand Binding Assay as potency assay ?



3.7 Have you ever performed in silico design of Monoclonal Antibodies using AI ?



Workshop 1 Audience Surveys

Bioassay Basics - Part 1

(Practice!) W1.1 What is your favorite vaction?



W1.2 What organization do you represent?



W1.3 How would you rate your proficiency level in bioassays?



W1.4 Which bioassay lifecycle challenge is most critical for you, now or ahead?



W1.5 Do you use an outlier's detection for your assay's readouts?



WS1.6 Which organism was first documented in the literature as an in vivo model to measure potency?



Workshop 2 Audience Surveys

Bioassay Automation Workshop

Part 1

W2.1 What kind of organization do you work with?



W2.2 How long have you worked with bioassays



W2.3 Do you use automation in your assays?



W2.4 If you automate your assays: what level of automation do you use?



W2.5 From which supplier are your automation devices?

Check back here in a few days for detailed results!

W2.6 Do you use automation in a GMP environment?



Part 2

W2.7 Which is your current biggest issue you have to solve regarding automation?

Check back here in a few days for detailed results!

W2.8 What are your expectations when you automate your assays? (choose the 3 most important)



W2.9 Which device do you use for automated cell counting?

Check back here in a few days for detailed results!

W2.10 Which position do you have in your organization?



W2.11 Did you ever do programming of automated bioassay procedures?



W2.12 What would you need/expect for future bioassay automation workshops/conferences?

Check back here in a few days for detailed results!

Workshop 3 Audience Surveys

Bioassay Basics - Part 2Bioassay Basics - Part 2

W3.1 In your experience, which areas most frequently require troubleshooting during method development?



W3.2 How do you currently run your CMC activities?

Workshop 4 Audience Surveys

Ongoing Procedure Performance Verification (OPPV) for Potency Methods

Part 1

W4.1 How familiar are you with the topic of OPPV (Ongoing Procedure Performance Verification)?



W4.2 What types of control charts do you use?



W4.3 Do you also perform more in-depth statistical analyses, and if so, which ones?

Check back here in a few days for detailed results!

W4.4 What software do you use for trend analysis?



W4.5 Which bioassay parameters are you tracking in the late stage?



Check back here in a few days for detailed results!

W4.6 What are the obstacles to establishing an ongoing montoring program?



W4.7 What rules do you apply to your control charts?



W4.8 Have you found control charts useful in practice?



Part 2

W4.9 At what stage of development do you begin bioassay trending?



W4.10 What optimization parameters have you identified while trending your late-stage bioassay?



W4.11 How often do you trend your late stage bioassay monitoring?



W4.12 What activities have you implemented for ongoing performance verification?

Check back here in a few days for detailed results!

W4.13 Is there a key message from this workshop that you would like to share?

Check back here in a few days for detailed results!

Thank You!!